IRB #

STUDY00015214

Title

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Principal Investigator

Rachel Cook

Study Purpose

The purpose of this study is to find out the side effects, good and/or bad, of the study drug, INCB052793, at different doses and in combination with other standard therapies in individuals with advanced malignancies (cancer).

Medical Condition(s)

Multiple myeloma, acute myeloid leukemia (AML), and myelodsyplastic syndromes (MDS)

Eligibility Criteria

Patients who have been diagnosed with multiple myeloma (MM), acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) who have failed, or are refractory to, available treatments.


Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

You will receive study treatment for as long as you do not experience serious side effects and as long as your cancer does not get worse. If it becomes appropriate to discontinue study treatment the investigator will continue to monitor you for up to 35 days after the last dose of study drug and will continue to collect information from you every three months indefinitely.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Incyte Corporation

Recruitment End

10/04/2020

Compensation Provided

No


Go Back